RxDoctor Payments Data

John Henson, MD

Internal Medicine · Gainesville, GANPI 1841293958

Payments from drug & device makers

$2,858in general payments, 2019–2025

Across 156 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$522
  • Lilly USA, LLC$483
  • Amgen$380
  • Pfizer$257
  • AbbVie$212
  • AstraZeneca$180
  • plus $824 from 17 others

What the payments were for

  • Food & beverage$2,858100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,858 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$121,116
Medicare patients
418
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$100,107
OzempicSemaglutide83$89,713
JanuviaSitagliptin Phosphate74$79,310
JardianceEmpagliflozin57$67,822
XareltoRivaroxaban36$36,660
FarxigaDapagliflozin Propanediol15$24,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,998
MyrbetriqMirabegron11$14,872
MounjaroTirzepatide13$13,356
Repatha SureclickEvolocumab23$12,449
SynthroidLevothyroxine Sodium107$10,141
Tresiba Flextouch U-200Insulin Degludec20$9,913
Breo ElliptaFluticasone/Vilanterol19$9,056
Combivent RespimatIpratropium/Albuterol Sulfate15$7,253
Tresiba Flextouch U-100Insulin Degludec11$6,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$257$100,107104 claims
Novo NordiskOzempic$522$89,71383 claims
MerckJanuvia$26$79,31074 claims
Boehringer IngelheimJardiance, Combivent Respimat$122$75,07472 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$100$33,63875 claims
AstraZenecaFarxiga, Symbicort$180$28,55030 claims
Lilly USA, LLCMounjaro$483$13,35613 claims
AbbVieSynthroid$212$10,141107 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →